MarginsXMarginsX
Home › Markets › Health Care › INKT

MiNK Therapeutics Inc. (INKT)

INKT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.35
+0.11% on the day
Market cap
$48.0M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerINKT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001840229
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
12.5 months
$7.5M cash at September 30, 2026
Share count, 1 year
+9.4%
2025-11-13 to 2026-11-06 · +48.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$47K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q."
10-Q 2026-11-12
Cash and burn$7.5M cash; operating cash flow -$1.8M a quarter.Report 2026-09-30
Shares outstanding5,133,645 (2026-11-06); 4,694,155 a year earlier; 34,519,540 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-10 on 2025-01-28Source 2025-01-28
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $47K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$200K-$2.6M-$1.3M$7.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$3.1M-$2.1M$8.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$2.7M-$1.7M$9.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$2.6M-$2.1M$13.4MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
$0-$2.9M-$941K$9.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$4.2M-$1.6M$1.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$2.8M-$1.3M$3.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$2.5M-$1.7M$4.6MNo debt tagsNeeds four quarters10-K 2026-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-11-07
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 267 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.8%
1 month-8.7%
3 months-15.1%
Year to date-16.2%
1 year-29.3%
From 52-week high-34.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ELOXEloxx Pharmaceuticals Inc.$12.75-3.04%$51.5M
GRMLGreenland Mines Ltd.$3.50-3.05%$51.9M
IMAImageneBio Inc.$3.20-7.78%$39.9M
TILInstil Bio Inc.$5.75-5.43%$39.0M
PMCBPharmaCyte Biotech Inc.$5.57-16.62%$59.8M
CRBUCaribou Biosciences Inc.$0.3528-2.51%$38.1M
CGTXCognition Therapeutics Inc.$0.6388-6.03%$60.8M
OKYOOKYO Pharma Limited$1.18-12.96%$61.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier